Jefferies Reiterates Buy Rating on BridgeBio Pharma (BBIO)

October 5, 2026 12:21 PM

Jefferies analyst Andrew Tsai reiterated a Buy rating and $110.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "New ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found